Lilly's Breakthrough Psoriasis Drug Ixekizumab (Taltz®) Approved in China for Moderate-to-Severe Plaque Psoriasis

On September 4, Eli Lilly (China) announced Taltz for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.^®(Ixekizumab Injection) has received marketing approval from the National Medical Products Administration (NMPA). This is a targeted IL-17A inhibitor that will bring clinical benefits to patients with psoriasis.

In August 2018, the National Medical Products Administration approved Taltz^®(Ixekizumab Injection) was included in the list of 48 urgently needed new drugs already marketed overseas. Benefiting from this policy, it was approved for market launch in just 12 months, allowing Chinese patients with psoriasis to access a new treatment option ahead of schedule!

Over 6 million psoriasis patients in China, with many unmet clinical needs

Surveys indicate that 28% of patients with psoriasis exhibit depressive symptoms, while another study reveals that the risk of suicidal ideation among psoriasis patients is 2.05 times that of the general population, imposing a substantial burden on patients, families, and society⁵. The efficacy of traditional systemic therapies is predominantly measured by PASI 50/75 response rates⁶⁻⁸. According to the “Global Report on Psoriasis” released by the World Health Organization (WHO) in 2016, 93% of patients aspire to achieve complete clearance of skin lesions, 94% expect rapid improvement in skin lesions, and 83% anticipate disease stability without progression.

Meanwhile, the treatment goals for psoriasis are continuously being redefined. For instance, major authoritative guidelines, such as the British Association of Dermatologists (BAD) guidelines on biologic therapy for psoriasis and the French guidelines on systemic treatment of moderate-to-severe psoriasis, all highlight higher treatment targets. With Taltz^®With the market launch of ixekizumab injection, these treatment goals are expected to be achieved.

High-Affinity Targeted IL-17A Inhibitor, Taltz^®(Ixekizumab Injection) Holds Promise for Complete Clearance of Skin Lesions

Tuozi^®(Ixekizumab Injection) binds with high affinity and specificity to the key pathogenic factors of psoriasis, interleukin-17A (IL-17A/A and IL-17A/F)12. According to the clinical trial UNCOVER-J data, when using Taltz^®(Ixekizumab Injection) After 16 weeks of treatment, 40% of patients achieved PASI100, 87% achieved PASI90, and 97% achieved PASI75.

Onset of action in one week, stable long-term efficacy, Tuozhi^®(Ixekizumab Injection) is superior to etanercept11 and ustekinumab

Tuozhi^®(Ixekizumab Injection) Significant improvement in skin lesions and pruritus symptoms can be achieved within 1 week of treatment; at 60 weeks, 55% of patients achieved PASI 100. With continued treatment, the clearance of skin lesions can be stably maintained for at least 4 years.

The UNCOVER-2 and IXORA-S studies demonstrated the superiority of Taltz® over etanercept and ustekinumab, with comparable safety profiles:

The UNCOVER-2 study’s primary clinical endpoint showed that at 12 weeks, Taltz^®(Ixekizumab Injection) The PASI 75 response rate was 90%, superior to etanercept (PASI 75 response rate 48%);

The primary clinical endpoint of the IXORA-S study showed that at 12 weeks, Taltz^®(Ixekizumab Injection) PASI 90 response rate of 73%, superior to ustekinumab (PASI 90 response rate of 42%).

Furthermore, Tuozi^®(Ixekizumab Injection) also won the Gold Award at the 2018 Medical Design Excellence Awards (MDEA). The auto-injector pen developed by Eli Lilly was designed with the participation of over 1,000 patients, featuring a simple and convenient operation method and human-centered design to facilitate patient use.

As of March 2019, Tuozi^®(Ixekizumab Injection) has been approved for marketing in 57 countries and regions worldwide. As of June 2019, it had benefited more than 92,000 patients.

References:

1. “Notice on Soliciting Opinions on the List of Clinically Urgent New Drugs Already Marketed Overseas” http://www.cde.org.cn/news.do?method=largeInfo&id=314651

2. Psoriasis Professional Committee, Dermatology and Venereology Branch of Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Psoriasis in China (2018 Abbreviated Edition)[J]. Chinese Journal of Dermatology, 2019, 52(4): 223-230.

3 Global report on psoriasis. © World Health Organization 2016. ISBN 978 92 4 156518 9

4 Dowlatshahi EA, et al. J Invest Dermatol. 2014 Jun;134(6):1542-1551.

5 Singh S, et al. J Am Acad Dermatol. 2017 Sep;77(3):425-440.e2.

6 Warren RB, et al. Lancet. 2017,389(10068):528-537.

7 Flytström I, et al. Br J Dermatol. 2008,158(1):116-121.

8 Yu C, et al. Eur J Dermatol. 2017,27(2):150-154.

9 Smith CH, et al. Br J Dermatol. 2017 Sep;177(3):628-636.

10 Amatore F, et al. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):464-483.

11 Griffiths CEM, et al. Lancet. 2015,386:541-551.

12 Liu L, et al. J Inflamm Res. 2016 Apr 19;9:39-50.

13 Saeki H, et al. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1148-55.

14 Data on file, Eli Lilly and Company, Leo path: LEO>Leo Storage>Clinical>LY2439821>I1F-JE-RHAT>Full Clinical Study Report>04 CSR body - full report.docx

15 Papp KA, et al. Br J Dermatol. 2018 Mar;178(3):674-681.

16 Lebwohl MG,et al. Sustained High Level of Efficacy and Favorable Safety of Ixekizumab in Psoriasis: 4 Years of Follow-up From UNCOVER-3. AAD 2019 poster 10011

17 Reich K, et al. Br J Dermatol. 2017 Oct;177(4):1014-1023.

18 Gordon KB, et al. N Engl J Med. 2016,375:345-356.

19 Chen K, et al. Oncotarget. 2017,8(28): 46381-46389.

20 Kimball AB, et al. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161.

21 Saeki H, et al. J Dermatol. 2017 Apr;44(4):355-362.

22 Callis Duffin K, et al. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113.

23 Langley RG, et al. Br J Dermatol. 2018 Jun;178(6):1315-1323.

24 Yosipovitch G, et al. J Sex Med. 2018 Nov;15(11):1645-1652.

25 2018 Medical Design Excellence Award Winners. https://mdeawards.mddionline.com/2018-winners

26 Callis Duffin K, et al. Med Devices (Auckl). 2016 Oct 12;9:361-369.

This article is sourced from Bioon. For more information, please download the Bioon APP (http://www.bioon.com/m/)